US-based pharmaceutical company Arrowhead Pharmaceuticals has applied to launch a Phase I/IIa clinical trial of ARO-INHBE, an investigational RNA interference (RNAi) therapy for treating obesity, in New Zealand.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,